Other

Teijin Limited

Teijin Pharma Limited

Nippon Welding Rod Co., Ltd.

Fuji Electric Co., Ltd.

Minoru Imai

Steven L Teig

Christine M Tarby

Tatsuki Shiota

Takaharu Tsutsumi

Wilna J Moree

Noriaki Endo

Minoru Furuya

Osami Takenouchi

Takahiko Hada

Takuya Morita

Yumiko Muroga

Masaki Sudoh

Ken-ichiro Kataoka

Ryo Sogawa

Hiroaki Makino

Yoshiyuki Matsumoto

Kenichiro Kataoka

Susumu Takeuchi

Gen Unoki

Tomomi Kosugi

Mika Takakuwa

Yuko Yamakoshi

Tomonori Yokoyama

Akinobu Nakanishi

Yoshiyuki Sawai

Kunio Minamizono

Joelle Le

Satoshi Sugiura

Dale Mitchell

Yasuhiro Oue

Naotaka Suzuki

Donald James Simpson

Eiji Matsumoto

Tetsuo Shibata

Masahiro Adachi

Yoshiro Yoshihiro

Robert Dale Mitchell

James Donald Simpson

Aiko Fujino

John Clifford Harris

Clifford John Harris

Yoshimi Onitsuka

An exposure management system includes dosimeters, wireless relay devices that wirelessly communicate with the dosimeters, and a monitoring device. The dosimeters are carried by workers for measuring exposure doses in a radiation management facility. The wireless relay devices transmit a monitor indication message that requests the dosimeters to provide respective responses that include information of measured exposure doses. The wireless relay devices receive the responses from the dosimeters by using allocated respective communication channels that are different from each other. Each dosimeter receives the monitoring indication message and generates a designated number of response times for providing a response to the monitor indication message, and determines a communication channel corresponding to each of the generated response times. The monitoring device is connected to the wireless relay devices for monitoring an exposure state of each of the workers through the wireless relay devices and dosimeters.

Exposure management system, dosimeter, and wireless relay device

The Pyrazolo[1,5-a]pyrimidine derivatives represented by formula I and their pharmaceutically acceptable salts exhibit excellent MAPKAP-K2 inhibiting activity. Drugs comprising the compounds as effective ingredients are therefore expected to be useful as therapeutic or prophylactic agents for MAPKAP-K2 mediated disorder, such as inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth. 

Pyrazolo[1,5-a]pyrimidine derivatives

The Pyrazolo[1,5-a]pyrimidine derivatives represented by formula I and their pharmaceutically acceptable salts exhibit excellent kinase inhibiting activity. Drugs comprising the compounds as effective ingredients are therefore expected to be useful as therapeutic or prophylactic agents for a protein kinase mediated disorder in which kinase is implicated, such as inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth. 

Pyrazolo[1,5-A] pyrimidine derivatives

The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides 4,4-(disubstituted)piperidine derivatives represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C-Calkyl adducts thereof, as well as pharmaceutical compositions comprising them as effective ingredients, which are useful for treatment or prevention of diseases associated with CCR3, such as asthma and allergic rhinitis. 

4,4-disubstituted piperidine derivatives having CCR3 antagonism

The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides compounds represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C-Calkyl adducts thereof, as well as pharmaceutical compositions comprising them as effective ingredients, which are useful for treatment or prevention of diseases associated with CCR3, such as asthma and allergic rhinitis. 

Piperidine derivatives having CCR3 antagonism

A torch for powder plasma buildup welding capable of readily attaining welding in conformity to any size of a pipe material to be subjected to welding, any configuration thereof and the like. A torch head is replaceably connected to a torch body. The torch body is provided with a gap formation spacer member which is abutted against an inner peripheral surface of the pipe material to keep a distance between an opening of a convergent nozzle of the torch head and the inner peripheral surface of the pipe material substantially constant during buildup welding. Also, the torch body is provided with a deflection restraint spacer member which is abutted against the inner peripheral surface of the pipe material to prevent deflection of the torch body in the pipe material during buildup welding.

Torch for powder plasma buildup welding

Cyclic amine derivatives and their use as drugs

A method of removing a binder from a green body capable of accomplishing the binder removal at a substantially reduced temperature and in a significantly reduced period of time. The binder mainly consists of a polymer material of ultraviolet degradation properties such as, for example, a polymer material having a main chain containing a tertiary carbon atom. The green body is irradiated with ultraviolet rays at a temperature within the range of 150.degree. C. to 300.degree. C. under an atmospheric pressure to rapidly carry out the photo degradation of the polymer material by ultraviolet rays, so that the binder may be readily removed from the green body.

Method for removing binder from green body

Growing community of inventors

Hino, Japan

Minoru Imai